Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities

Radiation Oncology

Table 5 Baseline characteristics of patients with LS-SCLC and ILA in this study

Variable	First-line treatment
	Chemoradiotherapy	Chemotherapy	P value
	(n = 25)	(n = 24)	P value
Age, ≥ 70/ < 70 years	16/9	18/6	0.5380
Sex, male/female	21/4	20/4	1.0000
ECOG-PS, 0/1/2 (0 vs. 1 or 2)	15/10/0	10/11/3	0.2578
Clinical stage^a, I/II/III (I vs. II/III)	1/1/23	1/5/18	1.0000
Brinkmann index, ≥ 400/ < 400	24/1	23/1	1.0000
Proportion of ILA area of any lung zone, 5%/10%/15–30%/30–50% (5%/10% vs. 15–30%/30–50%)	13/11/1/0	9/7/7/1	0.0106
V20, median (range), %	22 (10–32)

^aClinical staging was according to the 7th edition of the TNM classification of lung cancer [9]. LS-SCLC, limited-stage small-cell lung cancer
ECOG-PS, Eastern Cooperative Oncology Group performance status; ILA, interstitial lung abnormality; V20, percentage of normal lung receiving at least 20 Gy

ISSN: 1748-717X